Correlation between JAK2V617F mutation and inflammatory bowel disease in patients referring to Taleghani hospital, Tehran

authors:

avatar khadijeh koushki , avatar Mohammad Rostami Nejad , avatar Pedrami Azimzadeh , avatar Hamid Asadzadeh Aghdaei , avatar Abas Hajfathali , avatar Mohammad Amin Pourhosseingholi , avatar Hedyeh Balaei , avatar Davar Amani , * , avatar Mohammad Reza Zali , avatar Hossein Nobakht

Koomesh: Vol.17, issue 3; 603-612
article type: Research Article
received: September 01, 2015
accepted: December 02, 2015

how to cite: koushki K, Rostami Nejad M, Azimzadeh P, Asadzadeh Aghdaei H, Hajfathali A, et al. Correlation between JAK2V617F mutation and inflammatory bowel disease in patients referring to Taleghani hospital, Tehran. koomesh. 2016;17(3):e151207. 

Abstract

Introduction: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn;#39s disease (CD), is a chronic inflammatory disorder of the gastrointestinal tract. Genome-wide association study (GWAS) has shown that some of the genes of interleukin-23/T-helper 17 (IL-23/Th17) pathway such as Janus kinase -2 (JAK2) predispose the risk of IBD. 46/1 haplotype is common risk factors for both IBD and myeloproliferative neoplasms disease. In view of this shared genetic predisposition, we aimed to determine the frequency of the JAK2V617F mutation in Iranians with IBD for the first time. Materials and methods: In this case-control study, 100  IBD patients including 18 with CD and 82 UC were compared with 100 healthy controls  during 2011-2014. The genotypes were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) protocols and distribution of the JAK2 V617F mutations were compared in cases and control. To verify the method, patients with myeloproliferative neoplasms with JAK2V617F mutations were served as controls. Results: This study showed that JAK2V617F mutation was detected in neither patients nor controls. However, mutation was proved in all patients with myeloproliferative neoplasms that were used as positive control and their heterogeneities were determined. Conclusion: This study showed that other genetic mechanisms may play an important role in the pathogenesis of IBD. For further evaluation of this mutation, other studies with a larger number of patients and complications such as thromboembolic diseases, is recommended

References

  • 1.

    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.

  • 2.

    Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-99.

  • 3.

    Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002; 8: 567-573.

  • 4.

    Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517.

  • 5.

    Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.

  • 6.

    McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-337.

  • 7.

    Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-211.

  • 8.

    Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252.

  • 9.

    Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.

  • 10.

    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.

  • 11.

    Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40: 710-712.

  • 12.

    Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. N Nat Genet 2008; 40: 1319-1323.

  • 13.

    Brand S. Crohns disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohns disease. Gut 2009; 58: 1152-1167.

  • 14.

    Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-669.

  • 15.

    Stritesky GL, Muthukrishnan R, Sehra S, Goswami R, Pham D, Travers J, et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity 2011; 34: 39-49.

  • 16.

    Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010; 32: 605-615.

  • 17.

    Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, et al. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 2009; 136: 523-529.

  • 18.

    Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.

  • 19.

    Strober W. Why study animal models of IBD? Inflamm Bowel Dis 2008; 14: S129-S131.

  • 20.

    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.

  • 21.

    James C, Ugo V, Le Coudic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.

  • 22.

    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.

  • 23.

    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.

  • 24.

    Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-22792.

  • 25.

    Pingali SR, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 2009; 9: E25-E29.

  • 26.

    Wang YL, Vandris K, Jones A, Cross NCP, Christos P, Adriano F, et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2007; 22: 1289.

  • 27.

    Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012; 2012: 561-566.

  • 28.

    Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, et al. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol 2010; 150: 334-344.

  • 29.

    Kristinsson SY, Landgren O, Samuelsson J, Bjrkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010; 95: 1216-1220.

  • 30.

    Wang K, Zhang H, Kugathasan S, Annese V, Bradfield JP, Russell RK, et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 2009; 84: 399-405.

  • 31.

    Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.

  • 32.

    Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.

  • 33.

    Olcaydu D, Harutyunyan A, Jger R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450-454.

  • 34.

    Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.

  • 35.

    Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 2010; 690: 108-115.

  • 36.

    Lees C, Barrett J, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739-1753.

  • 37.

    Kuriakose E, Lascu E, Wang YL, Gjoni S, Cross NC, Baumann R, et al. The JAK2 V617F mutation seen in myeloproliferative neoplasms (MPNs) occurs in patients with inflammatory bowel disease: implications of a pilot study. Int J Clin Med 2013; 4: 10.

  • 38.

    Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-623.

  • 39.

    Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, et al. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 2008; 26: 149-155.

  • 40.

    Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434.

  • 41.

    Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548.

  • 42.

    Maher MM, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saud J Gastroenterol 2008; 14: 192.

  • 43.

    Karimi O, Crusius JBA, Coucoutsi C, Heijmans R, Sambuelli AM, Pea AS, Koutroubakis IE. JAK2 V617F mutation is not involved in thromboembolism in IBD. Inflamm Bowel Dis 2008; 14: 1606-1607.

  • 44.

    Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3: 617-62.

  • 45.

    Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J gastroenterol 2004; 99: 938-945.##.